{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T22:42:37Z","timestamp":1782168157342,"version":"3.54.5"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.jocn.2021.01.010","type":"journal-article","created":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T02:39:27Z","timestamp":1612147167000},"page":"79-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Bevacizumab as a surgery-sparing agent for spinal ependymoma in patients with neurofibromatosis type II: Systematic review and case"],"prefix":"10.1016","volume":"86","author":[{"given":"M. Harrison","family":"Snyder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonel","family":"Ampie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D.","family":"DiDomenico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok R.","family":"Asthagiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jocn.2021.01.010_b0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/0883073816666736","article-title":"Neurofibromatosis Type 2: presentation, major complications, and management, with a focus on the pediatric age group","volume":"32","author":"Ardern-Holmes","year":"2017","journal-title":"J Child Neurol"},{"issue":"02","key":"10.1016\/j.jocn.2021.01.010_b0010","doi-asserted-by":"crossref","first-page":"098","DOI":"10.1055\/s-0036-1579766","article-title":"Neurofibromatosis: a review of NF1, NF2, and schwannomatosis","volume":"05","author":"Kresak","year":"2016","journal-title":"J Pediatr Genet"},{"key":"10.1016\/j.jocn.2021.01.010_b0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1750-1172-4-16","article-title":"Neurofibromatosis type 2 (NF2): A clinical and molecular review","volume":"4","author":"Evans","year":"2009","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jocn.2021.01.010_b0025","doi-asserted-by":"crossref","unstructured":"Antinheimo J, Sankila R, Carpen O, Pukkala E, Sainio M, Jaaskelainen J. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology 2000;54:71\u201371. doi: 10.1212\/WNL.54.1.71.","DOI":"10.1212\/WNL.54.1.71"},{"issue":"4","key":"10.1016\/j.jocn.2021.01.010_b0030","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3171\/2010.11.SPINE10350","article-title":"Spinal ependymomas in neurofibromatosis Type 2: a retrospective analysis of 55 patients","volume":"14","author":"Plotkin","year":"2011","journal-title":"J Neurosurg Spine"},{"issue":"7","key":"10.1016\/j.jocn.2021.01.010_b0035","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.ctrv.2014.05.004","article-title":"Systemic therapy in neurofibromatosis type 2","volume":"40","author":"Lim","year":"2014","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10.1016\/j.jocn.2021.01.010_b0040","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11060-015-1925-8","article-title":"Clinical response associated with radiographic regression of a cervicomedullary ependymoma in a NF2 patient treated by bevacizumab","volume":"125","author":"Essayed","year":"2015","journal-title":"J Neurooncol"},{"issue":"4","key":"10.1016\/j.jocn.2021.01.010_b0045","first-page":"474","article-title":"The response of spinal cord ependymomas to bevacizumab in patients with neurofibromatosis Type 2","volume":"26","author":"Morris","year":"2017","journal-title":"J Neurosurgery: Spine"},{"issue":"1","key":"10.1016\/j.jocn.2021.01.010_b0050","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/neuonc\/nop010","article-title":"Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2","volume":"12","author":"Mautner","year":"2010","journal-title":"Neuro Oncol"},{"issue":"6","key":"10.1016\/j.jocn.2021.01.010_b0055","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/ane.12490","article-title":"Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2","volume":"133","author":"Farschtschi","year":"2016","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"10.1016\/j.jocn.2021.01.010_b0060","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s11060-017-2690-7","article-title":"Spinal ependymomas in NF2: a surgical disease?","volume":"136","author":"Kalamarides","year":"2018","journal-title":"J Neurooncol"},{"issue":"3","key":"10.1016\/j.jocn.2021.01.010_b0065","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s11060-016-2135-8","article-title":"Spinal cord ependymoma: a review of the literature and case series of ten patients","volume":"128","author":"Celano","year":"2016","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jocn.2021.01.010_b0070","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11864-015-0358-0","article-title":"Current management and treatment modalities for intramedullary spinal cord tumors","volume":"16","author":"Juthani","year":"2015","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"10.1016\/j.jocn.2021.01.010_b0075","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10143-017-0879-z","article-title":"Surgery for spinal intramedullary tumors: technique, outcome and factors affecting resectability","volume":"41","author":"Rashad","year":"2018","journal-title":"Neurosurg Rev"},{"issue":"4","key":"10.1016\/j.jocn.2021.01.010_b0080","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.spen.2015.10.008","article-title":"Diagnosis, management, and new therapeutic options in childhood neurofibromatosis type 2 and related forms","volume":"22","author":"Ruggieri","year":"2015","journal-title":"Semin Pediatric Neurol"},{"key":"10.1016\/j.jocn.2021.01.010_b0085","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1023\/A:1006470523052","article-title":"Radiation therapy and the management of intramedullary spinal cord tumors","volume":"47","author":"Isaacson","year":"2000","journal-title":"J Neurooncol"},{"issue":"5","key":"10.1016\/j.jocn.2021.01.010_b0090","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/cncr.10826","article-title":"Salvage chemotherapy for recurrent spinal cord ependymona","volume":"95","author":"Chamberlain","year":"2002","journal-title":"Cancer"},{"issue":"S3","key":"10.1016\/j.jocn.2021.01.010_b0095","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00586-017-5413-z","article-title":"Remarkable efficacy of temozolomide for relapsed spinal myxopapillary ependymoma with multiple recurrence and cerebrospinal dissemination: a case report and literature review","volume":"27","author":"Fujiwara","year":"2018","journal-title":"Eur Spine J"},{"issue":"1","key":"10.1016\/j.jocn.2021.01.010_b0100","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11060-016-2276-9","article-title":"Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohort","volume":"131","author":"Morris","year":"2017","journal-title":"J Neurooncol"},{"issue":"12","key":"10.1016\/j.jocn.2021.01.010_bib101","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/jmg.29.12.841","article-title":"A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity","volume":"29","author":"Evans","year":"1992","journal-title":"J Med Genet"},{"issue":"1","key":"10.1016\/j.jocn.2021.01.010_bib102","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00129492-200501000-00016","article-title":"Incidence of Vestibular Schwannoma and Neurofibromatosis 2 in the North West of England over a 10-year Period: Higher Incidence than Previously Thought","volume":"26","author":"Evans","year":"2005","journal-title":"Otol. Neurotol."}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586821000175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586821000175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:25:05Z","timestamp":1760822705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586821000175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":21,"alternative-id":["S0967586821000175"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2021.01.010","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bevacizumab as a surgery-sparing agent for spinal ependymoma in patients with neurofibromatosis type II: Systematic review and case","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2021.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}